Kornimate/medical-research-clean huggingface dataset:
the effect of point-of-care ultrasound guidance for distal radius fracture reduction

Conditions: Point-of-care Ultrasound, Distal Radius Fracture

Summary: distal radius (colle's) fractures in adult patients are commonly reduced in the emergency department before casting. standard of care currently requires that x-rays be performed before and after fracture reduction, and inadequate reductions may be subject to repeat attempts and are at a higher risk to require surgery. this study will assess the use of point-of-care ultrasound (pocus) in addition to standard care as a tool to decrease the angulation at the fracture site after a reduction is performed. if this angulation is decreased, it would suggest that pocus for distal radius fracture reduction could decrease the number of failed reduction attempts and therefore the number of repeated reduction attempts.


Eligibility criteria:
inclusion criteria: * radiographically confirmed distal radius fracture exclusion criteria: * patients who do not consent * patients with multiple acute injuries, open fractures, or other local fractures evident (a simple ulnar styloid fracture will not be considered an exclusion criterion) * patients with neurovascular compromise * patients with bilateral distal radius fractures * patients with minimally displaced distal radius fractures that do not require closed reduction before casting
study to investigate if sucking a coldamaris lozenge elutes sufficient iota-carrageenan to inactivate usual common cold viruses

Conditions: Common Cold; Viral Infection

Summary: coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. the goal of the study is to determine whether the iota-carrageenan content in the saliva of subjects who sucked coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common respiratory viruses causing common cold. at least 29 subjects will be screened, in order to get 24 subjects included.

coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. the goal of the study is to determine whether the iota-carrageenan content in the saliva of subjects who sucked coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common respiratory viruses causing common cold. at least 29 subjects will be screened, in order to get 24 subjects included. the primary objective is whether the mean iota-carrageenan concentration in saliva during sucking an iota-carrageenan containing lozenge reaches published ic90 values for hrv1a and hrv8. the secondary objectives are whether the mean iota-carrageenan concentration in saliva (µg/ml; base line corrected) during sucking an iota-carrageenan containing lozenge reaches the respective ic90/mic values (paired t-tests) of the clinical saliva samples for hrv1a, hrv8, hcov oc43, influenza virus h1n1n and coxsackie virus a10.

Eligibility criteria:
inclusion criteria: * personally signed and dated informed consent * healthy respiratory tract, no acute infection * age \> 18 years exclusion criteria: * subjects with signs of an acute respiratory infection * subjects with a known hypersensitivity to one of the ingredients * presence of pregnancy confirmed

Keywords: respiratory virus carrageenan coronavirus influenza virus human rhinovirus coxsackie virus carragelose iota-carrageenan
methods validation assessment for study of inflammatory skin disease

Conditions: Lichen Planus

Summary: 1. assess validity of methods involved in molecular studies of the skin in inflammatory skin disease 2. assess feasibility of methods for grafting fresh human skin (normal and diseased with inflammatory skin disease) onto an established xenograft murine model.

the use of fixed tissue specimens for research studies is attractive, because a large number of relevant specimens can be collected quickly from tissue registry. there is a current lack of knowledge regarding to what extent formalin fixation alters the identification of proteins in the skin with inflammatory dermatoses. this information would be important to assess when determining the limitations (or potentially lack thereof) of using fixed specimens in research. collaborators have successfully developed a murine model that can accept human skin xenografts. while those investigators have successfully demonstrated transplantation of healthy skin onto mice, it is unknown whether skin affected by inflammatory disease can be transplanted and, if so, whether the inflammatory skin disease remains, whether it spreads to involve host skin, or whether it resolves. determining feasibility of transplanting inflamed human skin using this model, as well as observing the course of this inflammation, are the next steps in advancing this potentially invaluable research modality.

Eligibility criteria:
inclusion criteria: - adults \>18 years with active cutaneous lichen planus with capacity to consent. exclusion criteria: * concurrent skin infection * wound healing disturbances * patients on systemic immunosuppressive medications. * lidocaine allergy * platelets \<10,000

Keywords: lichen planus proteomics xenograft model for lichen planus
study of urelumab in subjects with advanced and/or metastatic malignant tumors

Conditions: Malignant Tumors

Summary: the purpose of this study is to assess the safety and tolerability of bms-663513 in subjects with advanced and/or metastatic malignant tumors.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * subjects with previously treated advanced malignant solid tumor * eastern cooperative oncology group (ecog) performance status ≤ 1 * for certain subjects, willing and able to provide pre-treatment tumor sample exclusion criteria: * known or suspected central nervous system metastases or central nervous system as the only source of disease * other concomitant malignancies (with some exceptions per protocol) * active, known or suspected autoimmune disease

Keywords: advanced malignant tumors metastatic malignant tumors
recover-autonomic: platform protocol, appendix b (ivabradine)

Conditions: Long COVID; Long Covid19; Long Covid-19

Summary: this study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into covid-19 programs and subsequent treatment plans. this protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (pots), in pasc participants. the interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

the hypothesis is that some of the autonomic dysfunction symptoms are immune-mediated, so immunotherapy and other applicable therapies will result in improvement in autonomic symptoms. interventions will be added to the platform protocol as appendices. each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix.

Eligibility criteria:
inclusion criteria: * see nct06305780 for recover-auto: platform protocol level inclusion criteria which applies to this appendix (or sub-study) additional appendix b (ivabradine sub-study) level inclusion criteria: 1. abnormal active standing test defined as presence of orthostatic tachycardia (an increase of 30 beats per minute (bpm) or more in hr within 10 minutes upon standing without orthostatic hypotension) and experiencing orthostatic symptoms 2. compass-31 score \> 25 and not enrolled in the ivig appendix exclusions criteria: * see nct06305780 for recover-auto: platform protocol level inclusion criteria which applies to this appendix (or sub-study) additional appendix b (ivabradine sub-study) level exclusion criteria: 1. a person of child-bearing potential who is not taking effective contraception 2. use of the following medications: clonidine, tizanidine, amphetamines, and serotonin and norepinephrine reuptake inhibitors (snris) with the exception of modafinil 3. use of beta-blockers (any formulation), calcium channel blockers, midodrine, pyridostigmine, fludrocortisone, and guanfacine will be excluded unless participant is on a stable dose (\>4 weeks). participants on stable doses will be allowed to continue the medication throughout the study. 4. combination with verapamil or diltiazem which are moderate cyp3a4 inhibitors with heart rate reducing properties 5. lactating and breast-feeding women 6. severe hepatic impairment 7. use of drugs known to prolong the qt-interval (e.g., quinidine, disopyramide, bepridil, sotalol, amiodarone, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine 8. concomitant use of digoxin 9. participants who are pacemaker dependent 10. patients with hypokalemia (serum k+\<3.5 meq/l) 11. patients taking potassium-depleting diuretics 12. a history of congenital or acquired long qt syndrome, with or without torsade de pointes 13. patients with high degree av block such as mobitz ii

Keywords: pasc pots
an investigational drug, palbociclib (pd-0332991), is being studied in combination with velcade and dexamethasone in patients with multiple myeloma. patients must have received prior treatment for multiple myeloma.

Conditions: Multiple Myeloma

Summary: this is a phase 1/2 study evaluating the safety and anti-tumor activity of pd 0332991 in combination with velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.


Eligibility criteria:
inclusion criteria: * diagnosis of symptomatic multiple myeloma as defined by international myeloma working group (imwgurc). * phase 1: relapsed or relapsed/refractory myeloma after at least 1 previous treatments and with a life expectancy of more than 3 months. * phase 2: measurable (as defined by imwgurc) disease after at least 1 previous treatment. exclusion criteria: * history of allogeneic stem cell transplant. * phase 2 only: prior bortezomib therapy will only be allowed if there was a demonstrated positive response, and disease progression occurred off therapy. * must have not experienced significant blood level changes, e.g. very low platelets, while on previous bortezomib therapy * prior radiation therapy to \> 25% of the bone marrow (whole pelvis is 25%).
phase ii safety and efficacy study to evaluate a glaucoma therapy in open-angle glaucoma or ocular hypertension patients

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to determine the safety and iop-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * 18 years or older. * diagnosis of open-angle glaucoma or ocular hypertension. * logmar visual acuity not worse than 0.6. * other protocol-defined inclusion criteria may apply. exclusion criteria: * clinically relevant ophthalmic or systemic conditions. * other protocol-defined exclusion criteria may apply.

Keywords: open-angle glaucoma ocular hypertension poag
relationship between aldh2 and cin

Conditions: Radiographic Contrast Agent Nephropathy

Summary: the purpose of this clinical trial is to investigate the relationship between the gene polymorphism of aldehyde dehydrogenase 2 and contrast induced nephropathy and its mechanism.

patients undergoing coronary angiography or percutaneous coronary intervention will be recruited in this study after they sign the informed consent.5ml venous blood was extracted from the peripheral vein before the operation to detect the renal function, the genotype and enzyme activity of aldehyde dehydrogenase 2 ,and the levels of oxidative stress and inflammation.another 5ml venous blood was extracted from the peripheral vein 24-72 hours after the operation to detect the renal function and the levels of oxidative stress and inflammation.activated oxygen protein products , 4-hne and hs-crp as markers for oxidative stress and inflammation.the renal function index contains serum creatinine，urea nitrogen and cystatin c.

Eligibility criteria:
inclusion criteria: * patients undergoing elective coronary intervention or coronary angiography at yu qilu hospital. * all the patients or their guardians must sign the consent form before entering the trial. exclusion criteria: * patients with acute renal failure, renal transplantation, end-stage renal disease, or dialysis treatment, gfr \< 15ml/min. * use of renal toxicity drugs during the treatment, such as non steroidal anti-inflammatory drugs, etc. * patients who has used contrast agent 10 days before the operation. * cardiac shock, hypotension (systolic blood pressure \< 95mmhg),or hyper- tension with difficulty to control. * allergy to contrast media. * congestive heart failure (left ventricular ejection fraction\<40%), cardiac function nyha grade iv. * pregnancy or lactation.

Keywords: aldehyde dehydrogenase 2 contrast induced nephropathy gene polymorphism
epidural analgesia and delivery of second twin

Conditions: Epidural; Analgesia; Labor Pain

Summary: over an 8-year period, 124 twin pregnancies at gestational age ≥32 weeks with both twins presenting as a vertex and eligible for vaginal delivery were reviewed. excluded were patients with the following intrapartum factors which may affect mode of delivery of second twin: 1. presentation of the 2nd twin: breech or other than vertex; 2. monochorionic twins; 3. induction of labour; 4. difference in foetal weight between twin b and twin a ≥25%. the chi-square statistic was used to compare differences in the incidence of retained second twin between the groups.

the investigators conducted this prospective study in women with twins pregnancy planned for trial of vaginal delivery and gave birth between january 2014 and december 2019, in the department of obstetrics and gynaecology of the sabah maternity hospital, sabah specialized area, kuwait. the sabah maternity hospital is a tertiary care hospital for the country of kuwait with approximately 12500 deliveries per year. the study protocol was approved by the ethics committee.

Eligibility criteria:
inclusion criteria: .gestational age of 32 weeks, determined by an early ultrasound performed in the second trimester or certain last menstrual period; (2) both twins viable; (3) eligibility for vaginal delivery as defined by twin a being cephalic; and (4) no previous cesarean section. exclusion criteria: * underwent an elective or repeat cesarean section * presentation of twin b at delivery other than cephalic (breech, oblique or transverse presentation * induction of labour * the difference in foetal weight between twin b and twin a at delivery ≥25% .neonates were excluded if one was stillborn or had major congenital malformations.

Keywords: epidural analgesia labour
multi-electrocoagulation retinectomy for retinal re-detachment in silicone oil filled eye

Conditions: Retinal Detachment

Summary: retinal re-detachment in silicone oil filled eye, especially in the traumatic eye, is a complex retinal detachment with poor prognosis. in this study, the investigators try to apply a modified surgery as multi-electrocoagulation retinectomy to reattach the retina. here the investigators aimed to explore the safety and efficacy of this new surgical approach

the relaxing retinectomy is a useful surgery for retinal re-detachment in eyes with silicone oil filled. however, it has some obvious disadvantages such as the cut of the normal retina surrounding, leaving a large area of retinal deficiency and significant exposure of retinal pigment epithelium and choroid membranes. in this study, we try to apply a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina. instead of cutting through the proliferated retina directly, this new surgical approach adopts to cut the retina apart in a honeycomb shape with the help of electrocoagulation. in this way, we not only relax the traction of the proliferative membranes, but also reserve the rest retina to cover the rpe layers. based on the hypothesis above, we are aiming to explore the safety and efficacy of this new surgical approach

Eligibility criteria:
inclusion criteria: 1. age 5-60 years, male or female 2. the primary retinal detachment was caused by ocular trauma, and the vitreous body is filled with silicone oil now. 3. the presence of inferior retinal re-detachment located among 3-9 o'clock. exclusion criteria: 1. the primary retinal detachment was not caused by ocular trauma. 2. location of the re-detached retina is not mainly in the inferior of the eye. 3. the fundus is unobservable because of severe corneal opacity. 4. the contralateral eye is non-functional 5. serious heart, lung, liver and kidney dysfunction

Keywords: retinal detachment silicone oil retinectomy
study of cefepime-zidebactam (fep-zid) in complicated urinary tract infection (cuti) or acute pyelonephritis (ap)

Conditions: Complicated Urinary Tract Infection; Acute Pyelonephritis

Summary: this is a phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of fep-zid vs. meropenem in the treatment of hospitalized adults with cuti or ap. approximately 528 hospitalized adult subjects (≥ 18 years of age) diagnosed with cuti or ap will be enrolled in the study. the diagnosis of cuti or ap will be based on a combination of clinical symptoms and signs plus the presence of pyuria. the total duration of treatment with study drug is 7 to 10 days. each subject must remain hospitalized during the study drug treatment period; no outpatient parenteral antibiotic therapy is allowed.


Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 years of age 2. provide a signed written informed consent prior to any study-specific procedures 3. meet the clinical criteria for either cuti or ap 4. requires hospitalization to manage the cuti or ap 5. agrees to use effective methods of contraception exclusion criteria: 1. known or suspected disease that may confound the assessment of efficacy. 2. receipt of more than 72 hours of prior antibiotic therapy except for those failing prior antibiotic therapy and/or having documented uropathogen resistant to the prior therapy. 3. rapidly progressive illness such that the subject is unlikely to survive the study period. 4. pregnant or breastfeeding women 5. history of a seizure disorder requiring current treatment 6. creatinine clearance \< 15 ml/min or on renal dialysis 7. neutropenia or elevated liver enzymes 8. hypersensitivity to beta-lactam antibiotics 9. unlikely to comply with the protocol or the investigator considers that study participation may not be optimal for the subject
investigation of the effect of proximal and distal adductor canal block in knee replacement surgery

Conditions: Knee Osteoarthritis

Summary: to investigate the effect of adductor canal block applied with two different approaches in the treatment of pain after tka surgery on pain control and functional mobility.

this prospective randomized trial is randomly divided into 3 groups using the method. total knee arthroplasty is performed by the same surgical team. is applied. the patients were divided into proximal acb applied, distal acb applied and control groups.

Eligibility criteria:
inclusion criteria: * medications for unilateral tka surgery * patients aged 18-85 * asa 1-3 exclusion criteria: * patients under 18 years of age and over 85 years of age * patients with asa 4 and above * patients with cognitive impairment * patients with application site infection * patients allergic to local anesthesia * patients receiving anticoagulant therapy * patients with bleeding diathesis * patients with chronic opioid or substance use * patients with insulin-dependent diabetes mellitus * patients with neuropathy * patients with hepatic or renal failure * patients who do not accept the procedure to be applied

Keywords: adduktor canal block,knee artroplasti,postoperative pain
a dose ranging placebo-controlled double-blind study to evaluate the safety, pharmacokinetics and efficacy of 610 in participants with severe eosinophilic asthma

Conditions: Asthma

Summary: this study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

this is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 in adults with severe eosinophilic asthma. plan to recruit 24 subjects, and the subjects divided into 3 groups: 610 30mg group，100mg group, 610 300mg group，8 subjects in each dose group, of which 6 received the trial drug and 2 received placebo. the study is divided into screening period of 2 weeks, treatment period of 32 weeks and follow-up period of 12 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with asthma for ≥12 months * within 3 months before screening, treatment with medium to high dose inhaled corticosteroid（ics，inhaled fluticasone at a dosage of at least 500 μg, or equivalent, daily.）and at least one other additional controller medication, such as long-acting β₂ receptor agonist (laba), leukotriene receptor antagonist (ltra), theophylline, long-acting anticholinergic drugs (lama), etc. those medicine must be stable for ≥ 28 days prior to screening and baseline and must continue without dosage changes throughout the study * in the past 12 months prior to screening， at least one time asthma exacerbations history * pre-bronchodilator fev1 \<80% predicted value * asthma-related blood eosinophils ≥ 150 cells/μl within 3 months before administration exclusion criteria: * with clinically important lung diseases other than asthma that may affect safety or efficacy and evaluated by investigator. this includes lung infection, chronic obstructive pulmonary disease, bronchiectasis, hypersensitivity pneumonitis, pulmonary fibrosis, allergic bronchopulmonary aspergillosis, etc. * with other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes, eosinophilic granulomatosis with polyangiitis (egpa), or eosinophilic esophagitis * in past 12 months prior to screening，patients has done bronchial thermoplasty or radiotherapy or plan to do it during of the trial * with severe cardiac disease or uncontrolled or severe cardiac arrhythmia * poorly controlled systemic disease * active infection 7 day before screening * parasitic infection within 6 months before screening * at screening, hbsag or hcv ab or hiv ab or tp ab positive; hbsag or hcv ab positive need to be further tested of hbv dna titer detection or hcv rna detection (more than normal value range needs to be excluded) * subjects who have received any monoclonal antibody treatment of anti il-4ror anti-il-5/5r * vaccination history with live vaccines (including live attenuated vaccines) within 4 weeks before screening, or plan to receive during of the trial * participated in any interventional clinical trial and received intervention within 3 months before screening

Keywords: asthma eosinophilic asthma exacerbations 610 placebo